The Impact of Levodopa Therapy-induced Complications on Quality of Life in Parkinson's Disease Patients in Singapore
Affiliations
The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson's disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-induced complications and (4) QoL. Levodopa-induced complications including dyskinesia and OFF symptoms occurred in 13.5% and 55.9% of the study population, respectively. In patients who completed the 1-year follow-up, there was a trend suggestive of increasing dyskinesia duration, more disabling dyskinesia as well as longer, more sudden and unpredictable OFF periods. There was a significant decline in the overall QoL at follow-up, in particular, activities of daily living, emotional well-being, cognition and communication domains were the most affected. The multivariable analysis demonstrated that worsening of UPDRS IV total score over 1-year interval was associated with worsening in PDQ-Summary Index score (d = 0.671, p = 0.014). In conclusion, levodopa-induced complications had significant adverse impacts on QoL. This study substantiates the importance for clinicians to closely monitor and promptly manage levodopa therapy-induced complications that may arise in patients.
Lin H, Lin Y, Chiou C, Pan H Front Psychiatry. 2024; 15:1309989.
PMID: 39100849 PMC: 11294622. DOI: 10.3389/fpsyt.2024.1309989.
Shirgadwar S, Kumar R, Preeti K, Khatri D, Singh S J Alzheimers Dis. 2022; 94(s1):S109-S124.
PMID: 36463449 PMC: 10473071. DOI: 10.3233/JAD-220793.
Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim M, Alshehri S Front Pharmacol. 2022; 13:805388.
PMID: 35462934 PMC: 9021725. DOI: 10.3389/fphar.2022.805388.
Kovacs N, Bergmann L, Anca-Herschkovitsch M, Cubo E, Davis T, Iansek R J Parkinsons Dis. 2022; 12(3):917-926.
PMID: 34974438 PMC: 9108584. DOI: 10.3233/JPD-212979.
Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.
Prasad E, Hung S Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451813 PMC: 8398928. DOI: 10.3390/ph14080717.